肿瘤内CD61+巨核细胞的存在预示非小细胞肺癌预后不良。
Presence of intra-tumoral CD61+ megakaryocytes predicts poor prognosis in non-small cell lung cancer.
作者信息
Huang Weizhe, Zhao Shen, Xu Wei, Zhang Zhikui, Ding Xiangdong, He Jianxing, Liang Wenhua
机构信息
Department of Thoracic Surgery, the First Affiliated Hospital, Medical College of Shantou University, Shantou 515041, China.
Department of Thoracic Surgery/Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
出版信息
Transl Lung Cancer Res. 2019 Aug;8(4):323-331. doi: 10.21037/tlcr.2019.08.23.
BACKGROUND
Lung is a reservoir for megakaryocytes (MKs). The relationship between intra-tumoral MKs and non-small cell lung cancer (NSCLC) is unknown. We investigate relationship between high intra-tumoral MKs with the recurrence of NSCLC.
METHODS
The tissue sections of 629 patients with resected NSCLC were stained with hematoxylin, anti-CD61, anti-CD34 and stromal cell-derived factor-1 (SDF-1). CD61+ giant cells localized in CD34+ capillaries were identified as MKs. The impact of MKs and preoperative platelet count on disease-free survival (DFS) was investigated.
RESULTS
Overall, 18.9% of patients were positive for the presence of MKs. In univariate analysis, the median DFS of the MK+ group was shorter than the median DFS of the MK- group (69.1 . 80.5 months; P=0.021). Multivariate analysis indicated that MKs in tumor tissue was an unfavorable prognostic factor for DFS (HR 1.351, P=0.065), the impact of which was more significant in non-squamous cell carcinoma (NSCC) (HR 1.710, P=0.008) and in patients with N0 (HR 1.883, P=0.009). Although systemic platelet count of the MK+ group was significantly higher than the MK- group (270.6×10 . 243.6×10/L, P=0.007), the stratified subgroup DFS curves (P=0.003) showed that the effect of MKs on prognosis was independent of the blood platelet count.
CONCLUSIONS
Our results demonstrate that CD61+ MKs in tumor tissue predict unfavorable prognosis in NSCLC.
背景
肺是巨核细胞（MKs）的储存库。肿瘤内MKs与非小细胞肺癌（NSCLC）之间的关系尚不清楚。我们研究肿瘤内高MKs与NSCLC复发之间的关系。
方法
对629例接受手术切除的NSCLC患者的组织切片进行苏木精、抗CD61、抗CD34和基质细胞衍生因子-1（SDF-1）染色。定位于CD34+毛细血管中的CD61+巨细胞被鉴定为MKs。研究了MKs和术前血小板计数对无病生存期（DFS）的影响。
结果
总体而言，18.9%的患者MKs呈阳性。单因素分析显示，MK+组的中位DFS短于MK-组（69.1对80.5个月；P=0.021）。多因素分析表明，肿瘤组织中的MKs是DFS的不良预后因素（HR 1.351，P=0.065），在非鳞状细胞癌（NSCC）（HR 1.710，P=0.008）和N0患者（HR 1.883，P=0.009）中其影响更为显著。尽管MK+组的全身血小板计数显著高于MK-组（270.6×10对243.6×10/L，P=0.007），但分层亚组DFS曲线（P=0.003）显示，MKs对预后的影响独立于血小板计数。
结论
我们的结果表明，肿瘤组织中的CD61+ MKs预示NSCLC预后不良。
Zotero 插件